Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Epizyme, Inc.
  6. News
  7. Summary
    EPZM   US29428V1044

EPIZYME, INC.

(EPZM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Epizyme : Launches EZH2Now Testing Program With Quest Diagnostics

06/16/2021 | 07:55am EDT


ę MT Newswires 2021
All news about EPIZYME, INC.
06/29TURNING POINT THERAPEUTICS : Names New Chief Financial Officer
MT
06/28EPIZYME, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/28Epizyme, Inc. Announces Resignation of Paolo Tombesi as the Chief Financial O..
CI
06/28Epizyme, Inc. Announces That Matthew E. Ros Will Serve as Principal Financial..
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 3000 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell 3000E Growth Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) added to Russell Microcap Growth Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 3000E Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell 2500 Value Index
CI
06/25EPIZYME, INC.(NASDAQGS : EPZM) dropped from Russell Small Cap Comp Value Index
CI
More news
Financials (USD)
Sales 2021 44,1 M - -
Net income 2021 -250 M - -
Net cash 2021 62,2 M - -
P/E ratio 2021 -2,71x
Yield 2021 -
Capitalization 676 M 676 M -
EV / Sales 2021 13,9x
EV / Sales 2022 5,33x
Nbr of Employees 304
Free-Float 77,5%
Chart EPIZYME, INC.
Duration : Period :
Epizyme, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EPIZYME, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,63 $
Average target price 18,63 $
Spread / Average Target 181%
EPS Revisions
Managers and Directors
Robert B. Bazemore President, Chief Executive Officer & Director
Paolo Tombesi Chief Financial Officer
David M. Mott Chairman
Shefali Agarwal Executive VP, Chief Medical & Development Officer
Jeffery L. Kutok Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
EPIZYME, INC.-38.95%676
GILEAD SCIENCES, INC.18.01%86 563
BIONTECH SE251.15%69 138
WUXI APPTEC CO., LTD.32.49%67 035
REGENERON PHARMACEUTICALS19.60%59 833
VERTEX PHARMACEUTICALS-15.83%51 496